Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan-Mar;1(1):122-4.
doi: 10.4103/2045-8932.78096.

Diagnostic and therapeutic algorithm for pulmonary arterial hypertension

Ankit A Desai  1 , Roberto F Machado
Affiliations

Diagnostic and therapeutic algorithm for pulmonary arterial hypertension

Ankit A Desai et al. Pulm Circ. 2011 Jan-Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
PAH diagnostic algorithm. (ABG - Arterial blood gas; ALK-1 - Activin-receptor-like kinase; ANA - Anti-nuclear antibodies; BMPR2 - Bone morphogenetic protein receptor 2; CHD - Congenital heart disease; CMR - Cardiac magnetic resonance; CT - Computed tomography; CTD - Connective tissue disease; ECG - Electrocardiogram; FMHx - Family medical history; HHT - Hereditary hemorrhagic telangiectasia; HRCT - High-resolution computed tomography; LFTs - Liver function tests; LH - Left heart; PAP - Pulmonary arterial pressure; LVEDP - Left ventricular end-diastolic pressure; PAH - Pulmonary arterial hypertension; IPAH - Idiopathic pulmonary arterial hypertension; PCH - Pulmonary capillary hemangiomatosis; PE - Pulmonary thromboembolic disease; PFT - Pulmonary function test; PH - Pulmonary hypertension; PVOD - Pulmonary venoocclusive disease; RHC - Right heart catheterization; TEE - Transesophageal echocardiography; TTE - Transthoracic echocardiography; US - Ultrasonography; V/Q - Ventilation/perfusion lung scan; WHO - World Health Organization)
Figure 2
Figure 2
PAH treatment algorithm. (PAH - Pulmonary arterial hypertension; FC - Functional class; ERA - Endothelin receptor antagonist; PDE-I - Phosphodiesterase type 5 inhibitor; IV - Intravenous; PO - Oral; SC - Subcutaneous; NA - Not approved; WHO - World Health Organization; PAP - Pulmonary arterial pressure; RCT - Randomized controlled trial. Strength of recommendation: A - Strong recommendation; B - Moderate recommendation; C - Weak recommendation; D - Negative recommendation; E/A - Strong recommendation on the basis of expert opinion only; E/B - Moderate recommendation on the basis of expert opinion only; E/C - Weak recommendation on the basis of expert opinion only; E/D - Negative recommendation on the basis of expert opinion only)
See this image and copyright information in PMC

References

    1. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:78–84. - PMC - PubMed
    1. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76–81. - PubMed
    1. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation. 1987;76:135–41. - PubMed
    1. Raffy O, Azarian R, Brenot F, Parent F, Sitbon O, Petitpretz P, et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation. 1996;93:484–8. - PubMed
    1. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 1999;99:1197–208. - PubMed

LinkOut - more resources